Hsbc Holdings PLC Has $35.42 Million Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• HSBC increased its Zimmer Biomet stake by 16.3% in the second quarter, adding 57,778 shares to own 413,195 shares worth approximately $35.4 million. Institutional investors collectively hold 88.89% of the company.
• Analysts maintain a generally cautious outlook, with Zimmer Biomet receiving an average rating of “Hold” and an average price target of $104.42.
• Zimmer Biomet exceeded quarterly expectations, reporting $2.07 in EPS and $2.18 billion in revenue, while revenue grew 4.8% year over year. The company also declared a quarterly dividend of $0.24 per share, equating to a 1.0% annualized yield.

Hsbc Holdings PLC increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 16.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 413,195 shares of the medical equipment provider's stock after buying an additional 57,778 shares during the period. Hsbc Holdings PLC owned 0.22% of Zimmer Biomet worth $35,417,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Main Management ETF Advisors LLC lifted its holdings in shares of Zimmer Biomet by 1.0% during the fourth quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider's stock worth $986,000 after purchasing an additional 112 shares during the period. Citizens National Bank Trust Department grew its position in Zimmer Biomet by 17.6% in the 1st quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider's stock valued at $85,000 after buying an additional 141 shares during the last quarter. TD Private Client Wealth LLC increased its stake in Zimmer Biomet by 15.3% in the 4th quarter. TD Private Client Wealth LLC now owns 1,152 shares of the medical equipment provider's stock valued at $104,000 after buying an additional 153 shares during the period. Leonteq Securities AG raised its position in Zimmer Biomet by 5.3% during the 1st quarter. Leonteq Securities AG now owns 3,062 shares of the medical equipment provider's stock worth $277,000 after buying an additional 153 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. raised its position in Zimmer Biomet by 5.5% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 3,133 shares of the medical equipment provider's stock worth $282,000 after buying an additional 162 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ZBH shares. Weiss Ratings raised shares of Zimmer Biomet from a "sell (d+)" rating to a "hold (c-)" rating in a report on Tuesday, August 4th. BMO Capital Markets reissued a "market perform" rating and set a $96.00 price target on shares of Zimmer Biomet in a report on Thursday, August 6th. Canaccord Genuity Group raised their price objective on shares of Zimmer Biomet from $83.00 to $100.00 and gave the company a "hold" rating in a research report on Monday, August 10th. Citigroup lowered their price objective on Zimmer Biomet from $95.00 to $93.00 and set a "neutral" rating on the stock in a report on Thursday, May 28th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Zimmer Biomet in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $104.42.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $97.94 on Tuesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $106.88. The firm has a market capitalization of $18.68 billion, a P/E ratio of 23.83, a PEG ratio of 1.85 and a beta of 0.47. The company's fifty day moving average is $94.96 and its two-hundred day moving average is $91.62.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter last year, the firm posted $2.07 EPS. The business's revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet's dividend payout ratio (DPR) is 23.36%.

Zimmer Biomet Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.